Clinical Trial Update: 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating triapine (3-AP) with gemcitabine for refractory metastatic breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Male Breast Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Triapine (Triapine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Male Breast Cancer, Recurrent Breast Cancer | Phase 2 | Status: TERMINATED